Cancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E

Jiaqing Hao; Xiao Song; Jingjing Wang; Chengli Guo; Yan Li; Bing Li; Yu Zhang; Yanhui Yin

doi:10.18632/oncotarget.5973

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Cancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E

Jiaqing Hao _, Xiao Song, Jingjing Wang, Chengli Guo, Yan Li, Bing Li, Yu Zhang and Yanhui Yin

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:42028-42039. https://doi.org/10.18632/oncotarget.5973

Metrics: PDF 1986 views | HTML 2750 views | ?

Abstract

Jiaqing Hao1,*, Xiao Song1,*, Jingjing Wang1, Chengli Guo1, Yan Li1, Bing Li2, Yu Zhang1, Yanhui Yin1

1Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China

2Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA

*These authors have contributed equally to this work

Correspondence to:

Yu Zhang, e-mail: [email protected]

Yanhui Yin, e-mail: [email protected]

Keywords: cancer-testis antigen, MAGE-C2, SCF complex, cyclin E, cell cycle

Received: June 29, 2015 Accepted: October 09, 2015 Published: October 19, 2015

ABSTRACT

Cancer-testis antigen MAGE-C2 is normally expressed in testis but aberrantly expressed in various kinds of tumors. Its functions in tumor cells are mostly unknown. Here, we show that MAGE-C2 binds directly to the RING domain protein Rbx1, and participates in Skp1-Cullin1-F box protein (SCF) complex. Furthermore, MAGE-C2 can inhibit the E3 ubiquitin ligase activity of SCF complex. Ablation of endogenous MAGE-C2 decreases the level of cyclin E and accelerates cyclin E turnover by inhibiting ubiquitin-mediated proteasome degradation. Overexpression of MAGE-C2 increases the level of cyclin E and promotes G1-S transition and cell proliferation, and the results are further confirmed by knockdown of MAGE-C2. Overall, the study indicates that MAGE-C2 is involved in SCF complex and increases the stability of cyclin E in tumor cells.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5973

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Cancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E

Abstract